What kind of drug does Aceminid belong to?

Asciminib (Asciminib) is a targeted drug used to treat chronic myelogenous leukemia (CML) and is a third-generation tyrosine kinase inhibitor (TKI). It is unique in that its mechanism of action is different from earlier TKI drugs and is known as an "ABL myristoylpocket-binding inhibitor" (STI571). Traditional TKI drugs, such as imatinib (Imatinib) and nilotinib (Nilotinib), mainly inhibit BCR-ABLATP binding site of n>kinase blocks the proliferation of cancer cells, while acemini acts on the myristoyl binding site of ABL1kinase, thereby achieving the effect of inhibiting cancer cell proliferation.

Aximini's unique mechanism of action enables it to effectively target mutations that are resistant to first- and second-generation TKIs, especially the T315I mutation. The T315I mutation is a mutation that makes patients resistant to most common TKI drugs, and aceminib does not pass Different binding sites avoid the limitations of traditional TKIs, thereby inhibiting the mutated BCR-ABL protein. This property makes aceminib a breakthrough treatment option for patients with drug-resistant CML.

The clinical application of Asiminib is focused on patients with CML who have received multiple TKI treatments but failed, especially those who are resistant to conventional treatments. According to clinical trial results, Asiminib has shown a higher response rate in such patients, and its side effects are relatively controllable. Common side effects include fatigue, nausea, thrombocytopenia, etc.

Overall, aceminib not only fills a critical gap in the treatment of CML, but also represents the development trend of CML treatment, which is to fight the disease through more precise and diverse mechanisms. With a deeper understanding of BCR-ABL mutations, targeted drugs like aceminib that target specific mutations will further improve the long-term survival and quality of life of CML patients.